Product logins

Find logins to all Clarivate products below.


Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)

Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists move beyond longstanding reliance on topical and intralesional corticosteroids, which still dominate the treatment landscape despite realworld data demonstrating frequent switching and limited treatment persistence. Since 2022, the introduction of JAK inhibitors (Olumiant, Litfulo, and Leqselvi) has expanded systemic options for severe AA. As the AA treatment landscape continues to evolve, this report offers insight into prescribing trends to help new players understand current treatment practices and identify potential market opportunities for emerging therapies.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AA patients?
  • How have Olumiant and Litfulo been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of AA patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of AA patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Geography: United States

Key drugs covered: Corticosteroids (injectable, oral, topical), Litfulo, Olumiant, Leqselvi, tacrolimus

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Related Market Assessment Reports

Report
Gene Therapy – Access & Reimbursement – Access & Reimbursement – Gene Therapies for Rare Diseases (US)
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel reimbursement approaches are rapidly gaining importance. To assist developers of gene…
Report
Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Doublet or triplet chemotherapy, alone or in combination with angiogenesis inhibitors, remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS or BRAF mutations…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder of the hair follicles, characterized by painful, inflamed lesions often filled with fluid or pus. AbbVie’s Humira (…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Acute Coronary Syndrome – Landscape & Forecast – Disease Landscape & Forecast (G7)
Acute coronary syndrome (ACS) is a leading cause of morbidity and mortality in developed countries. Despite aggressive management of atherothrombotic risk factors through LDL-C lowering, blood-…